Internal Medicine, Pulmonary Disease · Hato Rey, PR
NPI
1649237181
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
735 Ponce de Leon Ave, Suite 716
Hato Rey, PR, 00917
Phone (787) 765-3079
Groups this clinician bills Medicare through
Medicare paid, 2024
$44K
1,068 services
Medicare patients, 2024
140
Average age 76
Drug cost, 2024
$1.4M
3,858 prescriptions
Company payments, 2025
$2,273
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Noel Totti III was code 99214 (office e&m - established), 238 times for 111 patients. In total Noel Totti III billed 1,068 services in 11 codes, and Medicare paid $44K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-09-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 238 | 111 | $88.02 | $21K |
| 94375 Pulmonary Function Testing | Office | 211 | 117 | $28.20 | $5,951 |
| 94200 Pulmonary Function Testing | Office | 211 | 117 | $11.48 | $2,421 |
| 94640 Treatment - Miscellaneous | Office | 125 | 66 | $6.17 | $771 |
| 94727 Pulmonary Function Testing | Office | 83 | 83 | $34.16 | $2,835 |
| 94729 Pulmonary Function Testing | Office | 83 | 83 | $41.52 | $3,446 |
| 99213 Office E&M - Established | Office | 64 | 51 | $71.44 | $4,572 |
| 99203 Office E&M - New | Office | 24 | 24 | $75.46 | $1,811 |
| 99212 Office E&M - Established | Office | 16 | 14 | $40.38 | $646 |
By year: 2022 $83K for 1,911 services; 2023 $58K for 1,307 services; 2024 $44K for 1,068 services.
Medicare prescription drug claims, 2024
In 2024, the drug Noel Totti III prescribed most often to Medicare patients was Wixela Inhub (Fluticasone Propion/Salmeterol), with 795 prescriptions and refills. In total Noel Totti III wrote 3,858 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Wixela Inhub Fluticasone Propion/Salmeterol | 795 | 821 | 219 | $110K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 468 | 478 | 81 | $316K |
| Fluticasone Propionate Generic | 340 | 387 | 124 | $6,335 |
| Montelukast Sodium Generic | 317 | 925 | 150 | $6,365 |
| Breo Ellipta Fluticasone/Vilanterol | 177 | 189 | 42 | $74K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 158 | 159 | 121 | $5,672 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 111 | 123 | 44 | $14K |
| Famotidine Generic | 96 | 208 | 52 | $1,144 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 95 | 99 | 21 | $22K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 93 | 93 | 26 | $44K |
| Symbicort Budesonide/Formoterol Fumarate | 88 | 90 | 26 | $21K |
| Pirfenidone Generic | 74 | 74 | 15 | $97K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 63 | 65 | 14 | $32K |
| Azithromycin Generic | 58 | 64 | 42 | $947 |
| Prednisone Generic | 52 | 62 | 44 | $237 |
Brand drugs: 1,407 claims; generic drugs: 2,451 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Noel Totti III $2,273 ($2,273 in general payments such as food, travel and fees) from 12 companies. The largest payer was GlaxoSmithKline, LLC. with $483.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 20 | $483 |
| AstraZeneca Pharmaceuticals LP AZN | 15 | $371 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 12 | $296 |
| Genzyme Corporation SNY | 12 | $294 |
| Janssen Pharmaceuticals, Inc JNJ | 8 | $203 |
| United Therapeutics Corporation UTHR | 9 | $162 |
| Merck Sharp & Dohme LLC MRK | 6 | $146 |
| Eli Lilly Export S.A. Puerto Rico Branch LLY | 5 | $122 |
| Amgen Inc. AMGN | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $56.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.